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ARDSAzithromycin is amember ofmacrolides, utilized in the treatment of infections. Independently, these antibiotics also
possess anti-inﬂammatory and immunomodulatory properties. Phospholipase A2 isotypes, which are implicated in
the pathophysiology of inﬂammatory lung disorders, are produced by alveolar macrophages and other lung cells
during inﬂammatory response and can promote lung injury by destructing lung surfactant. The aim of the study
was to investigate whether in lung cells azithromycin can inhibit secretory and cytosolic phospholipases A2,
(sPLA2) and (cPLA2), respectively, which are induced by an inﬂammatory trigger. In this respect, we studied the li-
popolysaccharide (LPS)-mediatedproduction or secretion of sPLA2 and cPLA2 fromA549 cells, a cancer bronchial ep-
ithelial cell line, and alveolar macrophages, isolated from bronchoalveolar lavage ﬂuid of ARDS and control patients
without cardiopulmonary disease or sepsis. Pre-treatment of cells with azithromycin caused a dose-dependent de-
crease in the LPS-induced sPLA2-IIA levels in A549 cells. This inhibition was rather due to reduced PLA2G2AmRNA
expression and secretion of sPLA2-IIA protein levels, as observed by western blotting and indirect immunoﬂuores-
cence by confocal microscopy, respectively, than to the inhibition of the enzymic activity per se. On the contrary,
azithromycin had no effect on the LPS-induced production or secretion of sPLA2-IIA from alveolar macrophages.
The levels of LPS-induced c-PLA2 were not signiﬁcantly affected by azithromycin in either cell type. We conclude
that azithromycin exerts anti-inﬂammatory properties on lung epithelial cells through the inhibition of both the ex-
pression and secretion of LPS-induced sPLA2-IIA, while it does not affect alveolar macrophages.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Macrolides belong to an old class of antibiotics containing 14-,
15-, or 16-membered lactone ring linked by glycosidic bonds with
sugars [for review, see 1]. They modulate the virulence activity of
both gram positive and negative bacteria by inhibiting proteinRespiratory Distress Syndrome;
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a@cc.uoi.gr (M.E. Lekka).synthesis through reversible binding to the 50S subunit of bacterial
ribosomes [2,3]. High concentrations of macrolides can be accumu-
lated in the lysosomal compartments of phagocytes, because of
their weak alkaline character, from where they are released to the
sites of inﬂammation. Macrolides are now being considered for
treatment of acute and chronic lung inﬂammatory diseases. In
particular, azithromycin suppresses quorum sensing, that regulates
bacterial density [4–6].
Apart from their antimicrobial activity, there is accumulating evi-
dence that macrolides can also act as immunomodulators. This was ini-
tially recognized in patients with diffuse panbronchiolitis, who
presented improved survival after treatment with erythromycin [5,7].
Macrolides act on a wide range of cells including bronchial epithelial
cells, alveolar macrophages, monocytes, eosinophils and neutrophils
[6,8]. They regulate leukocyte function and production of inﬂammatory
mediators, control mucus hyper-secretion and resolution of inﬂamma-
tion, and modulate host defense mechanisms [9]. It has been proposed
that macrolides exert their anti-inﬂammatory properties by inhibiting
nuclear factor κB and activating protein-1, suppressing the secretion
of pro-inﬂammatory cytokines and chemokines [7–10].
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leading to the production of pro-inﬂammatory mediators as well as
phospholipases A2 (PLA2) [12]. This group of enzymes catalyzes the
hydrolysis of the sn-2 ester bond of membrane phospholipids,
producing lyso-phospholipids and free fatty acids, such as arachidonic
acid, the precursor of eicosanoids. Members of the PLA2 superfamily
are implicated in lung inﬂammatory disorders [for review, see ref. 13],
while especially secretory, sPLA2 isotypes are considered as markers of
inﬂammation [14]. These enzymes play important role in the initiation
and ampliﬁcation of the inﬂammatory reaction. They induce
degranulation of mast cells and eosinophils and activate exocytosis in
macrophages. Furthermore, sPLA2s promote cytokine and chemokine
production from macrophages, neutrophils, eosinophils, monocytes,
and endothelial cells. These effects are mediated upon binding of
sPLA2s to speciﬁc receptors expressed on effector cells and are not
related to their enzymic activity [15].
Cytosolic PLA2, a Ca2+-dependent enzyme, is involved in cell
signaling processes. It produces arachidonic acid and its metabolites,
eicosanoids, which constitute a group of bioactive signaling molecules
[16].
So far, the information on the effect of azithromycin on suppressing
the expression of pro-inﬂammatory agents is not fully understood.
The aim of this study was to investigate whether macrolides and
especially azithromycin affects cPLA2 levels or the production and
secretion of sPLA2-IIA from LPS-activated human alveolar macrophages
and lung epithelial cells.
2. Materials and methods
A549 cell line, representing a model of type II alveolar cells, was
purchased from American Type Culture Collection (ATCC, Manassas,
VA); the cell culture media and its supplements were from Gibco
(BRL, Grand Island, NY) and the ﬂuorescent lipid reagents C12-NBD-PC
and C12-NBD-FA were from Avanti Polar Lipids (Alabaster, AL, USA).
Standard porcine sPLA2 type IIA [E.C. 3.1.1.4] was obtained from Sigma
Chemical Company (St Louis, MO, USA). Azithromycin, intravenous
solution, was obtained from Pﬁzer Hellas AE.
2.1. Patients
Ten consecutive mechanically ventilated patients were employed in
this study, 6 with early, moderate to severe ARDS (3with primary and 3
with secondary) and 4 control patients. Standard criteria for ARDS
diagnosis were based the Berlin Deﬁnition of ARDS [17].
Theﬁrst 48 h from the initiation of ARDS are considered as early stage
of the syndrome. The causes of primary ARDSwere pneumonia and aspi-
ration of gastric content. The risk factors for secondary ARDSwere severe
sepsis due to catheter-related infections and abdominal sepsis. The con-
trol group included intubated andmechanically-ventilated patients with
neuromuscular diseaseswhodeveloped ventilatory failure. The inclusion
criteria for control subjectswere as follows: no evidence of cardiopulmo-
nary disease, PaO2/FiO2 N 400 mm Hg, without evidence of systemic in-
ﬂammation. All patients underwent diagnostic bronchoalveolar lavage
(BAL) according to ref. [14]. The protocol was approved by the review
board for human studies of the University Hospital of Ioannina, while
the patients or the next of kin gave a written informed consent to the
study.
2.2. Cell cultivation and treatment conditions
Human alveolar macrophages were isolated fromBAL ﬂuid of control
and ARDS patients. BAL ﬂuid was ﬁltered for mucus removal and centri-
fuged at 500 g for 10min at 4 °C for BAL. The sediment, representing the
isolated cells, was washed twice with phosphate-buffered solution
(PBS), pH 7.4, and was ﬁnally re-suspended in RPMI-1640 culture
medium. Cell count and viability were measured after cell stainingwith Trypan Blue exclusion dye. Alveolar macrophage (AM) population
was puriﬁed by a negative-isolation protocol, using Dynabeads (Dynal
LTD, UK) [18].
AMs (1×106 cells/well)were cultured in a growthmediumconsisting
of RPMI-1640 without phenol red (to avoid interference with the ﬂuori-
metric assays), supplemented with 10% FBS, 2 mM L-glutamine, Ca2+/
Mg2+ and antibiotic cocktail, at 37 °C in a 5% CO2 incubator. The cells
were allowed to adhere for 3 h and then, the supernatants were
collected, while adherent cells were washed twice with 37 °C PBS. Cells
were made quiescent by incubation for 24 h in medium without FBS
prior to the addition of LPS and azithromycin.
Human A549 cells (6–8× 105 cells/well)were cultured in Ham's F12
K medium supplemented with 10% fetal bovine serum, 2 mM L-gluta-
mine and antibiotic cocktail, at 37 °C in 5% CO2 complete medium
until they reached ~80% conﬂuence. Subconﬂuent cells were made qui-
escent for 24 h by incubating in serum-free Ham's F12K.
AMandA549 cellswere treatedwith 1 μg/mL LPS (Sigma, Saint Louis,
USA) for 24 h. In separate experiments, the cells were pre-treated with
azithromycin (5 μg/mL, 20 μg/mL and 40 μg/mL for qRT-PCR experi-
ments) for 1 h before the addition of LPS. Reference samples included
untreated cells (control) and cells treated only with azithromycin.
After the incubation period, the cell supernatantswere collected and
centrifuged at 800 g for 10 min at 4 °C, the sediment was discarded and
the 800g centrifuged supernatants were aliquoted and kept at−80 °C
until analysis. Adherent cells were harvested by scrapping in ice-cold
PBS,washed andwereﬁnally re-suspended into 1mL PBS. Homogeniza-
tion was assessed by sonication and aliquots were stored at−80 °C for
less than 2weeks for PLA2 determination. Total proteinwas determined
by the method of Bradford [19]. For western blot experiments, cells
were lysed directly on the Petri dish after the addition of 50 μL electro-
phoresis sample buffer [25 mM Tris–HCl, pH 6.8, 4% (w/v) SDS, 10%
glycerol, 10% (v/v) β-mercaptoethanol, 0.006%, w/v, bromophenol
blue]. The lysates were collected and boiled for 5 min, aliquoted and
stored at−80 °C until use. All the cell samples from ARDS and control
patients were analyzed each one separately.
2.3. Fluorimetric determination of total PLA2 activity
Total Ca2+-dependent PLA2 activity in cell homogenates and cell
supernatants was measured by a ﬂuorimetric assay developed in our
laboratory [20,21]. The incubation mixture contained 240 μL of
10 mM Tris–HCl buffered solution, 2 mM Ca2+, pH 7.4, and 5 μΜ
C12-NBD-PC (1-palmitoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-
yl)amino]dodecanoyl}-sn-glycero-3-phosphocholine) as a ﬂuores-
cent substrate. The reaction started with the addition of the source
of the enzyme containing 5–15 μg of total protein. Incubation took
place for 4 h. Excitation and emission wavelengths were adjusted
to 475 and 535 nm respectively. The enzymic activities were calcu-
lated from the slope of the response curve by using C12-NBD-FA as
an internal standard.
To investigate whether azithromycin blocked the activity of the
enzyme per se, the above assay was performed using standard sPLA2
preparations dissolved in normal saline (0.8 × 10−3 IU) and the cells
were pre-incubated for 30 min with a ﬁnal concentration of 50 μg/mL
azithromycin.
2.4. Analysis of PLA2 isoenzymes by western blotting
Secretory, sPLA2 type IIA, cytosolic cPLA2 and its activated-
phosphorylated form, pcPLA2, were analyzed by western blotting:
Samples from whole-cell protein extracts or cell supernatants were
subjected to 15% SDS-PAGE, followed by immunoblotting, onto a
polyvinylidine diﬂuoride (PVDF) membrane. Nonspeciﬁc binding sites
were blocked by incubation with 5% skim milk in TBS containing 0.1%
Tween-20 (TBS-T), for 4 h at 4 °C. The membranes were then incubated
overnight with polyclonal rabbit anti-human sPLA2 group IIA (dilution
Fig. 1. Effect of azithromycin (Az) on the LPS-induced total PLA2 activity in A549 cells. The
levels of PLA2 total activity were determined with a ﬂuorimetric assay using C12-NBD-PC
as a substrate. Values represent mean ± SD of three independent experiments.
*P b 0.05: signiﬁcant difference from control A549 cells; #P b 0.05: signiﬁcant difference
from LPS-treated A549 cells.
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USA), polyclonal rabbit anti-human cPLA2 (dilution 1:1000, sc-454,
Santa Cruz Biotechnology, Inc. USA) and polyclonal rabbit anti-human
phosphorylated cPLA2 antibody (Ser 505) (dilution 1:1000) (#2831,
Cell Signalling Technology, Beverly, MA, USA). After washing with
TBS-T, blots were incubated for 2 h at room temperature with the
goat anti-rabbit IgG-HRP antibody (dilution 1:7000, sc-2004, Santa
Cruz Biotechnology, CA, USA). The immunoreactive bands were
visualized with ECL chemiluminescence detection kit (Amersham
Biosciences) and their intensities were analyzed by using the ImageJ
image processing program (U.S. National Institutes of Health, Bethesda,
Maryland, USA). Equal protein loading was conﬁrmed by using anti-β-
actin mouse monoclonal IgG1 antibody (C4) (dilution 1:500, sc-47778,
Santa Cruz, CA, USA) and the goat anti-mouse IgG-HRP (dilution
1:7000, sc-2005, Santa Cruz, CA, USA) as a secondary antibody.
2.5. Intracellular protein expression of sPLA2-IIA
The LPS-induced expression of sPLA2-IIA was studied in A549 cells
by indirect immunoﬂuorescence followed by analysis by confocal
microscopy. The cells were grown on cover slips and treated with the
appropriate LPS concentration for 24 h. At the end of the incubation
the cells were washed twice with PBS before being ﬁxed with 4%
paraformaldehyde in PBS. After two washings with PBS, the samples
were brieﬂy rinsed with an NH4Cl solution in order to quench free
paraformaldehyde. Cells were then permeabilized with 0.1% Triton X-
100 in PBS for 4 min at room temperature and incubated for 15 min
with blocking buffer (10% FCS in PBS). Primary anti-sPLA2-IIA antibodies
were incubated with the cells for 45 min at room temperature in 10%
fetal calf serum in PBS. After washingwith PBS, the cells were incubated
with donkey anti-rabbit IgG secondary antibodies (diluted in 10% FCS in
PBS) conjugated with Alexa ﬂuorophores, purchased from Invitrogen.
Then, coverslips weremounted on glass slides usingMowiol containing
100 mg/mL diazabicyclo[2.2.2]octane (Sigma). Images were obtained
on a Leica TCS SP5 II scanning confocal microscope, using the 63×
HCX PL APO 1.3 NA objective and were subsequently processed with
LAS AF and Adobe Photoshop software.
2.6. Total RNA isolation and qRT-PCR
For qRT-PCR experiments, cells were lysed directly on the Petri dish
after the removal of the supernatant, with the addition of lysis buffer
solution provided by the NucleoSpin RNA II kit (Macherey-Nagel,
GmbH & Co. KG, Germany). Total RNA was isolated according to the
manufacturer's recommended protocol. RNA integrity and purity was
checked electrophoretically and veriﬁed with the criterion of an
OD260/OD280 absorption ratio N 1.7.
Real-time PCR was performed using the iScript One-Step RT-PCR kit
with SYBR green (Bio-Rad Laboratories, Hercules, CA), using forward
and reverse primers from Qiagen (USA) for PLA2G2A, PLA2G4A and
GAPDH human genes, with the last used as a reference housekeeping
gene.
Total RNA (100 ng) in a 25 μL total volume was ﬁrst incubated at
50 °C for 10 min to synthesize cDNA, heated at 95 °C for 5 min to
inactivate the reverse transcriptase, and then subjected to 35 thermal
cycles (94 °C for 40 s, 60 °C for 40 s, and 72 °C for 1 min) of PCR
ampliﬁcation and 40 cycles from 55 °C to 95 °C (1 °C increase/cycle)
for melting curve analysis using an MJ mini thermal cycler (Bio-Rad,
Hercules, CA). Regarding A549 cells, three separate RNA isolations
were analyzed in eight qRT-PCR runs, in duplicates for each experimen-
tal condition, whereas three separate RNA isolations analyzed in ﬁve
qRT-PCR runs were performed for BAL AM, in duplicates for each
experimental condition.
Relative quantization of qPCR data from A549 RNA samples was
carried out according to the method of Pfafﬂ [22], using GAPDH as an
internal reference. Quantitative RT-PCR results were calculated asfold-increase in gene mRNA versus fold-increase in GAPDH mRNA.
Data from qPCR from AM RNA samples were recorded and calculated
with Bio-Rad CFX Manager software applying ΔΔCt method.
2.7. Statistics
Values were expressed as mean ± SD of three independent
duplicate experiments. Comparisons were assessed by one-way
ANOVA followed by post hoc comparisons with the Bonferroni method.
The level of statistical signiﬁcance was set at P b 0.05.
3. Results
3.1. Effect of azithromycin on LPS-induced total PLA2 activity in A549 cells
As depicted in (Fig. 1), total Ca2+-dependent PLA2 activity,
measured ﬂuorimetrically, was signiﬁcantly increased in LPS-
treated A549 cells in comparison with the untreated cells: control:
[(4.10±0.98)nmolC12-NBD-FA/h/mg protein] and LPS: [(7.09±
1.03)nmolC12-NBD-FA/h/mg protein, Pb0.05]. This increase was
totally blocked in samples pre-treated with 5 or 20 μg/mL
azithromycin, prior to the addition of 1 μg/mL LPS, resulting in PLA2
values similar to the control: [5 μg/mL azithromycin + LPS:
(5.15 ± 0.34) nmol C12-NBD-FA/h/mg protein, 20 μg/mL
azithromycin + LPS: (4.06 ± 0.63) nmol C12-NBD-FA/h/mg protein].
Interestingly, azithromycin alone had no effect on total PLA2 activity
of the untreated-control cells. Additionally, reference experiments
with standard porcine sPLA2-IIA showed that the presence or
absence of azithromycin did not affect the enzymic activity
(Table 1). Moreover, the endogenous Ca2+-independent PLA2
activity levels measured in the presence of 10 mM EDTA (a chemical
chelator) by the ﬂuorimetric method in cell homogenates in the
present study, were inconsiderable.
3.2. Effect of azithromycin on LPS-induced PLA2 isoenzymes in A549 cells
Western blot experiments revealed that cPLA2 and its activated
form, pcPLA2, were present at signiﬁcant but invariable levels, both in
untreated and LPS-treated cell homogenates (Fig. 2A and B).
Azithromycin did not modify the cPLA2 or pcPLA2 levels under any of
our experimental conditions.
Cell lysates were also examined for sPLA2-IIA production: As shown
in Fig. 3A and B, only the samples treatedwith LPS showed an induction
of sPLA2-IIA protein. Interestingly, azithromycin signiﬁcantly reduced
Table 1
Effect of azithromycin on standard sPLA2-IIA activity.
Sample sPLA2-IIA activity
(nmol FA/h/mL sample)
Standard porcine sPLA2 6.82 ± 0.38
Standard porcine sPLA2 + 50 μg/mL azithromycin 6.74 ± 0.43
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sPLA2-IIA was secreted only upon treatment with LPS. Pre-treatment
with 5 μg/mL azithromycin reduced the LPS-induced secretion of
the enzyme, while with 20 μg/mL azithromycin, the sPLA2-IIA signal
was totally abolished (Fig. 3 A and C). The expression of sPLA2 was
also tested by confocal microscopy. Consistently with the western
blotting data, LPS induced a robust expression of sPLA2 (Fig. 4B),
which was inhibited by azithromycin in a dose-dependent manner
(Fig. 4C and D). In untreated cells we could not detect endogenous
expression of sPLA2 (Fig. 4A). A possible reason for the absence of en-
dogenous sPLA2 detection in untreated A549 cells is the low concen-
tration of sPLA2, below the detection limit of WB technique.Fig. 2. Effect of LPS and azithromycin (Az) on cPLA2 and p-cPLA2 production in A549 cells. (A) In
Cell homogenates were analyzed bywestern blotting using anti-cPLA2 and pcPLA2 antibodies. A
intensities of pcPLA2 intensities analyzed by the ImageJ image processing program. Values rep3.3. Effect of azithromycin on LPS-induced PLA2-IIA production in human
alveolar macrophages
3.3.1. Cytosolic PLA2
Under our experimental conditions, cPLA2 and its activated-
phosphorylated form, pcPLA2, were slightly expressed at the protein
level, in both cells from control and ARDS patients. The protein band
did not change signiﬁcantly after cell treatment with azithromycin,
LPS, or both (Fig. 5A).
3.3.2. Secretory PLA2-IIA
Production and secretion of sPLA2-IIA was induced by LPS in the
alveolar macrophages from control, but not from ARDS patients
(Fig. 5B). In particular, a low signal on western blotting was detected
in the AM cell homogenate from control patients, but the majority of
the protein was detected in the extracellular medium under treatment
with LPS 1 μg/mL for 24 h. Azithromycin did not affect the production
or the secretion of the LPS-induced sPLA2-IIA (Fig. 5B), contrary to
A549 cells. Even in higher concentration of azithromycin (40 μg/mL),
no inhibitory effect was observed on the production or secretion of
the sPLA2-IIA protein (Fig. 5C).cubationwith LPS took place in the presence (5 and 20 μg/mL) or absence of azithromycin.
ntibodies against β-actinwere used as control of protein loading. (B) Bar graphs represent
resent mean ± SD of three independent experiments.
Fig. 3. Effect of LPS and azithromycin (Az) on sPLA2-IIA induction inA549 cells: (A) The gels are representative of one cell preparation under different treatment conditions. Untreated cells
were used as a reference for each experiment. Incubation with LPS took place in the presence (5 and 20 μg/mL) or absence of azithromycin. Cell homogenates were analyzed by western
blotting using anti-sPLA2-IIA antibodies. Antibodies againstβ-actinwere used as control of protein loading. (B) Bar graphs represent intensities of sPLA2-IIA inA549 cell lysates analyzed by
the ImageJ image processing program. Values representmean± SD of three independent experiments. (C) Bar graphs represent intensities of sPLA2-IIA in A549 supernatants analyzed by
the ImageJ image processing program. Values representmean± SD of three independent experiments. *P b 0.05: signiﬁcant difference from control; #P b 0.05: signiﬁcant difference from
samples treated with LPS; §P b 0.05: signiﬁcant difference from samples treated with LPS + azithromycin 5 μg/mL.
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Fig. 4. Effect of azithromycin (Az) on LPS-induced expression of sPLA2 in A549 cells: sPLA2-IIA was detected by immunoﬂuorescence microscopy after incubation with appropriate
secondary antibodies labeled with Alexa 594. Samples were analyzed using a Leica TCS SP5 II scanning confocal microscope, using the Leica 63× HCX PL APO 1.3 NA objective. Images
were acquired using the Leica Software and ﬁleswere subsequently processed in LASAF and Adobe Photoshop. (A) Control A549 cells without activationwith LPS; (B) A549 cells activated
with 1 μg/mL LPS; (C) A549 cells treatedwith 5 μg azithromycin/mL, 30min prior to activationwith 1 μg LPS; (D) A549 cells treatedwith 20 μg azithromycin/mL, 30min prior to activation
with 1 μg LPS. The bar represents 50 μm.
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the extracellular medium of AM from ARDS patients, the enzyme was
not detectedwithin the cells. It is noteworthy that sPLA2-IIAwas detect-
ed only in the BAL ﬂuid from ARDS patients, contrary to the control
patients (Fig. 6).3.3.3. PLA2G2A and PLA2G4A mRNA expression
The qRT-PCR data revealed that PLA2G2AmRNA is slightly expressed
in untreated A549 cells (cycle threshold 29 from 100 ng RNA sample).
This expression presented a 2.9 ± 1.4-fold increase after LPS treatment
(P b 0.05). Azithromycin 20 μg/mL alone did not affect the expression
levels of PLA2G2A mRNA (0.8 ± 0.3). However, the LPS-induced in-
crease of PLA2G2A mRNA expression was inhibited by pre-incubation
of the A549 cells with azithromycin 20 μg/mL (1.6 ± 1.6, P b 0.05)
(Fig. 7A). The genes' expression was normalized to the housekeeping
gene of GAPDH. Regarding samples treated with 5 μg/mL azithromycin
(±LPS), the signal was very low.
We did not detect any PLA2G2AmRNA expression neither in control
nor in ARDS RNA samples from AMs.
On the contrary, PLA2G4A mRNA expression was measured in AM
RNA samples from both control and ARDS patients: The expression
levels were not altered signiﬁcantly after treatment of AMs from control
patients with LPS (1.2 ± 0.5), 40 μg/mL azithromycin alone (0.9 ± 0.4)
or LPS + azithromycin (40 μg/mL) (0.8 ± 0.4) as compared to the
untreated cells (P N 0.5) (Fig. 7B). Regarding ARDS AM, similar pattern
of PLA2G4A expression was observed before or after the incubation ofthe cells with LPS (0.9 ± 0.9), azithromycin 40 μg/mL (0.8 ± 0.6) or
LPS + azithromycin 40 μg/mL (0.7 ± 0.8) as compared to control.
4. Discussion
In this study, we demonstrated that pre-incubation of A549 cells, a
model of alveolar epithelial cells, with azithromycin, suppressed the
LPS-induced total PLA2 activity, secretory PLA2-IIA protein levels as
well as the LPS-induced PLA2G2A mRNA expression. In parallel,
azithromycin could not inhibit the activity of standard sPLA2-IIA
in vitro. Thus, the reduction of total PLA2 activity in azithromycin pre-
treated cells could be due to suppressed endogenous expression of
sPLA2-IIA, as it was shown by confocal microscopy and qRT-PCR data.
Primary cultures of alveolar macrophages (AMs) responded in a
different way: LPS induced the production and secretion of sPLA2-IIA
in cells from patients without cardiopulmonary disease, contrary to
cells from patients with ARDS, where sPLA2-IIA protein was observed
only in the extracellular medium. Azithromycin did not suppress the
LPS-induced sPLA2-IIA protein expression, even at the high concentra-
tion of 40 μg/mL, or the total PLA2 activity in the AM of any group of
patients. Under all our experimental conditions, the protein levels of
cPLA2 and its activated form, pcPLA2, were low, and were not modiﬁed
after treatment with LPS or azithromycin.
Lung injury is a consequence of diffuse alveolar damage. Alveolar
cells produce a variety of inﬂammatory cytokines that recruit neutro-
phils to the lung parenchyma. Activation of these cells causes an
excessive release of cytokines, reactive oxygen species, and proteases,
Fig. 5. Effect of LPS and azithromycin (Az) on the production of cPLA2, aswell as the production and secretion of sPLA2-IIA, from alveolarmacrophages. Cellswere isolated from four control
and six ARDS patients. Incubationwith LPS took place in the presence (5 and 20 μg/mL) or absence of azithromycin. Analysis took place bywestern blotting using 5 μg protein loading and
appropriate antibodies for cPLA2, pcPLA2 and sPLA2-IIA. Antibodies against β-actin were used as control of protein loading. (A) Levels of cPLA2 and its activated form, pcPLA2. (B) Intracel-
lular levels of sPLA2-IIA. (C) Levels of sPLA2-IIA in cell supernatants. Gel images are representative of one AMpreparation from control and one fromARDSpatient under different treatment
conditions.
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Fig. 6. Detection of sPLA2-IIA in BAL ﬂuid: The levels of sPLA2-IIA were analyzed by
western blotting using anti-sPLA2-IIA antibody in BAL ﬂuids from six ARDS and four
control patient samples.
Fig. 7. (A) Relative expression of PLA2G2A mRNA in A549 cells. The data are the means ± SD o
isolations. (B) Relative expression of PLA2G4A mRNA in AM. The data are the means ± SD of ﬁ
lations. *P b 0.05: signiﬁcant difference from untreated; (#P b 0.05): signiﬁcant difference from
1295E. Kitsiouli et al. / Biochimica et Biophysica Acta 1852 (2015) 1288–1297including PLA2, which disturb the permeability of the alveolar-capillary
membrane and can lead to the development of ARDS. Walkey and
Wiener investigated the association between administration of
macrolide antibiotics and clinical outcomes in patients with ARDS
[23]. They found that patients who received early treatment with
macrolides showed signiﬁcant reduction in mortality. In our study, we
used LPS for the activation of epithelial cells. LPS induces an excessive
production of pro-inﬂammatory substances, including various PLA2
isoforms [24–28]. Secretory PLA2s are known to play a role in the
pathogenesis of many inﬂammatory diseases: Increased levels of
sPLA2 have been detected in the plasma and biological ﬂuids of patients
with ARDS, acute pancreatitis, rheumatoid arthritis, pneumonia, etc.
[14,29]. sPLA2s cause the liberation of free fatty acids, such as arachidon-
ic acid (AA) and lyso-phospholipids [30] from membrane phospho-
lipids, while they can destruct lung surfactant and promote the
development of lung injury [13].
The fact that the LPS-induced sPLA2-IIA production and release were
suppressed after pre-treatment of A549 cells with azithromycin reveals
its anti-inﬂammatory properties on alveolar epithelial cells. Our
ﬁndings are in agreement with the observations of Walkey andWienerf eight qRT-PCR experiments with duplicate samples from three independent total mRNA
ve qRT-PCR experiments with duplicate samples from three independent total mRNA iso-
samples treated with LPS.
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a possible explanation for above observations.
Alveolar macrophages are key effector cells, representing the ﬁrst
line of pulmonary defense. They exert pathogen recognition, antigen
processing and phagocytosis and produce inﬂammatory mediators,
amongwhich sPLA2-IIA is a major contributor. LPS induced the produc-
tion and secretion of sPLA2-IIA in AM from control patients, as expected.
However, in cells from ARDS patients, stimulated ex vivo with LPS, the
enzyme was detected only in the extracellular medium and not within
the cells. This ﬁnding, combinedwith the fact that sPLA2-IIAwas detect-
ed in BAL ﬂuid from ARDS patients only, and not in BAL ﬂuid from
control patients, supports the concept that under activation the injured
lung secretes sPLA2-IIA.
Despite the fact that our RNA preparation was quite pure and we
have tried 3 different sets of primers, i.e., two synthetic pairs, 5′ GGCA
CCAAATTTCTGAGCTACA 3′ (Forward)/5′ TTATCACACTCACACAGTTGAC
TTCTG 3′ (Reverse), 5′ CAACAGATCCAGGGAGCATT 3′ (Forward)/5′
AGGCCGTCTTGTTTGTTCTG 3′ (Reverse) and one set purchased from
Qiagen, which we ﬁnally used in this study, we did not detect the
PLA2G2A mRNA transcript in AM cells by qRT-PCR. On the contrary,
the mRNA transcript of PLA2G4A was readily detectable in either A549
cells or AMs. The above differences could be due to possible high turn-
over of the PLA2G2AmRNA especially in AMs. Synthesis of sPLA2-IIA is
regulated in a complex manner and is highly depended on the target
cell type and the stimulus employed [33]. This could be reﬂected by
altered PLA2G2A mRNA turnover rates in different cells in response to
various stimuli, through different signaling pathways. Such a phenome-
non has been reported for themRNA of PLA2G4A in A549 cells, where an
inﬂammatory signal results in activation and binding of a transcription
factor to the PLA2G4A transcript thereby leading to its stabilization
and expression and prevents its degradation [34]. Besides, high levels
of protein expression despite undetectable mRNA levels have been
reported in other cases as well [35]. Thus, we could hypothesize that,
in LPS-treated cells, a high turnover of the mRNA transcript of
PLA2G2A, following its translation, might prevent its detection by qRT-
PCR. In any case, the conclusions drawn in the present study are based
on speciﬁc activity assays, aswell as on consistent analysis of the protein
levels by immunoblotting, and provide evidence for the expression
levels of this enzyme both at the activity and the protein level.
The reason why we could not detect sPLA2-IIA intracellular levels
can be explained by the possibility that it is retained loosely in
formations near the extracellular membrane [36], which are detached
during the cell harvesting and collected with the cell supernatant. The
difference in the response of AM from control or ARDS patients to LPS
could be explained by immune tolerance of cells from ARDS patients
to the prompt formation of new pools of the enzyme within the cells.
This is in agreement with a previous work where we found impaired
sPLA2-IIA production by stimulated macrophages from patients with
ARDS [18].
The fact that azithromycin in our primary AM cultures did not
suppress LPS-induced sPLA2-IIA levels intracellularly or extracellularly
even in high concentration of 40 μg/mL signiﬁes that these cells are
allowed to function even in the presence of the antibiotic. This ﬁnding
is in consistency with other studies where the ability of macrolides
did not suppress, but rather enhanced phagocytosis of apoptotic
epithelial cells and neutrophils by macrophages [37,38]. Finally,
azithromycin did not affect the cPLA2 expression at mRNA or protein
levels in AMs. This fact could be of interest, since cPLA2 participates in
signal transduction and regulates innate immune responses. However,
in a previous work [18], we had found that LPS increases p-cPLA2 levels
in alveolar macrophages from control patients but this could have been
due to themore potent LPS stimulus, whichwas a higher LPS concentra-
tion (25 μg/mL, instead of 1 μg/mL used in the present study). Other
investigators suggested that azithromycin inhibits cPLA2 activity in
LPS-stimulated J774A.1 cells, based on indirect experimental evidence,
where inhibition of arachidonic acid release was observed. However,they did not observe any suppression on cPLA2 mRNA levels, which is
in agreement with our results, where azithromycin did not affect
neither the protein nor the mRNA levels of cPLA2, and it did not inhibit
total PLA2 activity in vitro [39].
Our results show a different response of LPS-treated alveolarmacro-
phages and A549 cells to azithromycin as far as sPLA2-IIA expression is
concerned. Apart from the different cell types, this phenomenon may
be due to the function of alveolar epithelial type II cells as immune
boosters in activating AMs through an autocrine loop involving the pro-
duction of inﬂammatory molecules [40]. NF-κB signaling pathway,
whichplays a prominent role in the regulation of sPLA2-IIA gene expres-
sion [41], could be involved in this event. Recently, it was shown that
the anti-inﬂammatory activity of azithromycin in epithelial and endo-
thelial cells, was associated with the inhibition of NF-κB activation
after LPS instillation in the lung [42]. This was not the case for AMs
since azithromycin did not inhibit the NF-κB pathway in a model of
LPS-induced pulmonary neutrophilia [43]. In summary, in A549 cells
azithromycin inhibits the LPS-induced sPLA2-IIA expression possibly
through inhibition of the NF-κB signaling pathway, contrary to AMs
where azithromycin does not affect the NF-κB pathway.5. Conclusions
Based on our experimental data, we suggest that azithromycin
exhibits a protective anti-inﬂammatory activity on epithelial cells
through the suppression of LPS-induced sPLA2-IIA expression and
secretion, an enzyme known to be implicated in the pathogenesis of
lung injury. These results could explain the beneﬁcial effect of
azithromycin in certain diseases, such as panbronchiolitis and acute
lung injury.Transparency Document
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